[go: up one dir, main page]

BR0311189A - Composições farmacêuticas contendo polimorfo a de flibanserin - Google Patents

Composições farmacêuticas contendo polimorfo a de flibanserin

Info

Publication number
BR0311189A
BR0311189A BR0311189-0A BR0311189A BR0311189A BR 0311189 A BR0311189 A BR 0311189A BR 0311189 A BR0311189 A BR 0311189A BR 0311189 A BR0311189 A BR 0311189A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
flibanserin
polymorphic
containing pharmaceutical
compositions containing
Prior art date
Application number
BR0311189-0A
Other languages
English (en)
Other versions
BRPI0311189B8 (pt
BRPI0311189B1 (pt
Inventor
Thomas Friedl
Guido Bernhard Edmund Radtke
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0311189A publication Critical patent/BR0311189A/pt
Publication of BRPI0311189B1 publication Critical patent/BRPI0311189B1/pt
Publication of BRPI0311189B8 publication Critical patent/BRPI0311189B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS CONTENDO POLIMORFO A DE FLIBANSERIN". A presente invenção refere-se a composições farmacêuticas orais contendo polimorfo A de flibanserin, métodos para sua preparação e uso das mesmas como medicamento.
BRPI0311189A 2002-05-22 2003-05-19 composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso BRPI0311189B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
EP02011224.9 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (3)

Publication Number Publication Date
BR0311189A true BR0311189A (pt) 2005-02-22
BRPI0311189B1 BRPI0311189B1 (pt) 2019-04-09
BRPI0311189B8 BRPI0311189B8 (pt) 2021-05-25

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311189A BRPI0311189B8 (pt) 2002-05-22 2003-05-19 composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso

Country Status (25)

Country Link
EP (1) EP1511489B1 (pt)
JP (1) JP3919788B2 (pt)
KR (1) KR101054237B1 (pt)
CN (3) CN1655789A (pt)
AT (1) ATE499939T1 (pt)
BR (1) BRPI0311189B8 (pt)
CA (1) CA2483597C (pt)
CY (1) CY1111470T1 (pt)
DE (1) DE60336225D1 (pt)
DK (1) DK1511489T3 (pt)
EA (1) EA007185B1 (pt)
EC (1) ECSP045493A (pt)
ES (1) ES2361994T3 (pt)
HR (1) HRP20041092B1 (pt)
IL (1) IL164440A0 (pt)
ME (1) MEP55308A (pt)
MX (1) MXPA04011487A (pt)
NO (1) NO329414B1 (pt)
NZ (1) NZ537253A (pt)
PL (1) PL211062B1 (pt)
RS (1) RS51718B (pt)
SI (1) SI1511489T1 (pt)
UA (1) UA80135C2 (pt)
WO (1) WO2003097058A1 (pt)
ZA (1) ZA200408151B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009541443A (ja) * 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017128932A1 (zh) * 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
AU2002331361B2 (en) * 2001-08-02 2008-06-05 Sprout Pharmaceuticals, Inc. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
ES2361994T3 (es) 2011-06-27
CY1111470T1 (el) 2015-08-05
JP3919788B2 (ja) 2007-05-30
DE60336225D1 (de) 2011-04-14
KR101054237B1 (ko) 2011-08-08
CN101002780A (zh) 2007-07-25
RS51718B (sr) 2011-10-31
MEP55308A (en) 2011-05-10
WO2003097058A1 (en) 2003-11-27
CN102240289A (zh) 2011-11-16
HRP20041092B1 (hr) 2013-05-31
CA2483597A1 (en) 2003-11-27
EA007185B1 (ru) 2006-08-25
EP1511489B1 (en) 2011-03-02
EA200401515A1 (ru) 2005-06-30
SI1511489T1 (sl) 2011-06-30
KR20040111668A (ko) 2004-12-31
RS98704A (sr) 2006-12-15
PL372457A1 (en) 2005-07-25
CN1655789A (zh) 2005-08-17
JP2005530787A (ja) 2005-10-13
ZA200408151B (en) 2006-06-28
BRPI0311189B8 (pt) 2021-05-25
BRPI0311189B1 (pt) 2019-04-09
AU2003240672A1 (en) 2003-12-02
IL164440A0 (en) 2005-12-18
MXPA04011487A (es) 2005-02-14
NO20044547L (no) 2004-12-17
ECSP045493A (es) 2005-03-10
CA2483597C (en) 2010-02-09
EP1511489A1 (en) 2005-03-09
NZ537253A (en) 2007-09-28
NO329414B1 (no) 2010-10-18
PL211062B1 (pl) 2012-04-30
ATE499939T1 (de) 2011-03-15
HRP20041092A2 (en) 2005-06-30
UA80135C2 (en) 2007-08-27
DK1511489T3 (da) 2011-05-02

Similar Documents

Publication Publication Date Title
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
SE0001899D0 (sv) New compounds
PT1506185E (pt) Compostos novos e sua utilizacao
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
SE0302546D0 (sv) New compounds
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
BRPI0509524A (pt) formas cristalinas de n-desmetilclozapina
BR0308201A (pt) Derivados de quinolina
BRPI0409175A (pt) preparação farmacêutica oral para antagonistas de bombeamento de próton
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
BRPI0414732A (pt) piridilacetilenos para uso como radiotraçadores e agentes de imageamento
BRPI0412737A (pt) sistema semi-sólidos contendo derivados de azetidina
DE602006002328D1 (de) Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
BR0301547C1 (pt) composição farmacêutica para tratar patologia fúngica compreendendo lectina km+, composição farmacêutica para prevenir patologia fúngica compreendendo lectina km+, uso de lectina km+ para preparar medicamento para tratar patologia fúngica, uso de lectina km+ para preparar medicamento para prevenir patologia fúngica
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/496, 9/20

Ipc: A61K 31/496 (2011.01), A61K 9/20 (2011.01), A61P 2

Free format text: PARA: INT. CL. A61K 31/496, 9/20; A61P 25/16, 25/18, 25/20, 25/22, 25/24, 25/28

Ipc: A61K 31/496 (2011.01), A61K 9/20 (2011.01), A61P 2

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SPROUT PHARMACEUTICALS, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.